Alto Neuroscience (ANRO) Q3 2026: Burn Rate Beat Funds a Busy 2027

Alto Neuroscience lost $0.54 per share in the third quarter of 2026, beating expectations. The company generates no product revenue, so the outperformance reflects the timing and pace of research spending rather than any commercial activity.

Research and development costs climbed to $18.16 million from $10.53 million a year earlier, with general and administrative expenses also rising, both driven by the accelerating PACE program for lead candidate ALTO-207. Despite that widening spend, net loss came in at $25.1 million for the quarter, tighter than analysts expected.

The more significant number in the report is $319.8 million in cash. A registered direct offering completed in July 2026 raised approximately $94.6 million in net proceeds and pushed that balance high enough that management believes operations are funded through 2030, removing near-term dilution risk and giving the company room to run its ALTO-207 Phase 3 monotherapy trial and adjunctive trial simultaneously.

Four catalysts are now lined up before the second half of 2027. FDA feedback on Phase 3 trial design is expected in late 2026 or early 2027, alongside Phase 1 data on a modified-release formulation and blinded PACE-1 safety results to inform dose selection. ALTO-300 Phase 2b topline data in major depressive disorder is targeted for the first half of 2027, and ALTO-100 Phase 2b bipolar depression data is expected by mid-2027.

The PACE-1 Phase 2b trial is enrolling roughly 178 adults with treatment-resistant depression and is tracking toward topline data in the second half of 2027. PACE-2, the Phase 3 adjunctive trial, is expected to initiate in early 2027 pending FDA alignment, and PACE-3, the Phase 3 monotherapy arm announced in July 2026, is slated to begin in the second half of 2027. Alto's ALTO-207 intellectual property is expected to provide protection into the mid-2040s.